The U.S. Food and Drug Administration (FDA) approved Caplyta on December 20, 2019, for the treatment of schizophrenia in adults.

Zealand Pharma reveals favorable topline outcomes from the 16-week Phase 1b trial with escalating doses of long-acting amylin analog petrelintide.

The U.S. Food and Drug Administration (FDA) approved Dayvigo on December 20, 2019, for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults.

Kyverna's KYV-101 gets U.S. FDA IND approval for treating patients with hard-to-treat Stiff-Person Syndrome in the KYSA-8 Phase 2 study.

The U.S. Food and Drug Administration (FDA) granted approval to Padcev on December 18, 2019, for the treatment of adults with locally advanced or metastatic urothelial cancer, a common type of bladder cancer.

Jun 26th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The U.S. Food and Drug Administration (FDA) approved golodirsen on December 12, 2019, for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.

Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn’s disease.

The U.S. Food and Drug Administration (FDA) approved voxelotor on November 25, 2019, for the treatment of sickle cell disease in adults and children aged 12 years and older.

Neurotech Pharmaceuticals, Inc. Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel).

The U.S. Food and Drug Administration (FDA) approved cenobamate on November 21, 2019, for the treatment of partial-onset seizures in adults.

Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma.